Research on the development of the composition of complex action dental films with calcium hydroxyapatite

The aim. Development of the composition of dental films for remineralization, treatment and prevention of dental hyperesthesia, prevention of the formation of microbial biofilms, elimination of pathogenic microflora. Methods. Determination of crystallographic characteristics, uniformity of particle distribution and their ability to aggregation was carried out by microscopy, viscosity – by rotational viscometer, pH-potentiometrically. The tensile strength of the films, the ability to stretch and lengthen, the strength of the bioadhesive bond were investigated by a texture analyzer, the thickness of the films – by calipers. Antimicrobial activity was determined by the disk-diffusion method and by the effectiveness of antimicrobial preservatives. Results. The choice of CHA concentration (10 %) was based on the analysis of literature sources. Structural-mechanical and organoleptic studies established the feasibility of using a combined system with the inclusion of purified water, glycerin and macrogol 400. The study of sedimentation and aggregation stability of the samples showed a uniform distribution of particles in samples from PVA, HEC, HPC. Films from Sodium Alginate, PVP, Na-CMC and HPMC were excluded from the work due to unsatisfactory properties. Structural-mechanical and physico-chemical properties allowed us to choose 5 % PVA as the film former, and 4 % glycerin as the plasticizer. The concentrations of API (metronidazole and chlorhexidine) were selected based on antimicrobial activity and preservative effect. Conclusions. As APIs, CHA – a remineralizing, anti-caries agent, metronidazole and chlorhexidine – antimicrobial components were selected. The introduction of CHA is rational in a complex dispersion medium, metronidazole as a suspension with glycerin, chlorhexidine as a 20 % solution. The composition of the film base was substantiated. The concentrations of metronidazole and chlorhexidine bigluconate were determined. The developed drug met the specifications of the MQC